About
Team
Portfolio
News
Contact
eFFECTOR Therapeutics' Lead Product Candidate, eFT508, Receives Orphan Designation from FDA for Treatment of Diffuse Large B-Cell Lymphoma
May 9, 2017
|
In
Portfolio Company News
|
By
usvpAdminer
Prev
Next
Cookies are used on our website. Press Accept if you consent to the use of cookies, press Decline if you do not consent to the use of cookies.
Accept
Decline